Canada Markets closed

SomaLogic, Inc. (SLGC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.41+0.44 (+3.39%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close12.97
Open13.08
Bid12.55 x 1000
Ask14.20 x 900
Day's Range12.81 - 13.58
52 Week Range9.83 - 14.72
Volume542,625
Avg. Volume849,156
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    SomaLogic Reports Third Quarter 2021 Financial Results

    Increase of 40% in third quarter revenue to $20.0 million over the corresponding period in 2020Increase of 112% in year-to-date revenue to $58.6 million over the corresponding period in 2020 Raising 2021 full year revenue guidance to $77-79 millionAddition of 61 new customer accounts expands and diversifies customer baseExpansion of leadership team with senior life science executivesSubstantial cash and investments of $676 million enabling continued growth acceleration initiatives Company to hos

  • GlobeNewswire

    SomaLogic to Present at the Stifel 2021 Virtual Healthcare Conference

    NEW YORK and BOULDER, Colo., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Stifel 2021 Virtual Healthcare Conference. SomaLogic’s management is scheduled to participate in a fireside chat on Wednesday, November 17, 2021 at 11:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s webs

  • GlobeNewswire

    SomaLogic announces strategic collaboration with University Hospitals Cleveland Medical Center to treat diabetic patients at high risk of cardiovascular disease

    BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with one of the nation’s leading academic medical centers, University Hospitals Cleveland Medical Center, where they will evaluate the impact of the company’s SomaSignal™ tests on the medical management of diabetic patients who are at a higher risk of cardiovascular disease. As part of the collaboration, University Hospitals (UH) Cle